stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Shares outstanding
Insmed, Inc.'s shares outstanding at the end of fiscal 2025 was $199.0M, up 21.3% from $164.0M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $218.8M. Over the past ten years it has ranged from $58.6M (fiscal 2015) to $199.0M (fiscal 2025) — the current reading is the highest in ten years. Insmed, Inc. ranks 39th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $199.0M | 21.32% |
| FY2024 | $164.0M | 16.81% |
| FY2023 | $140.4M | 14.14% |
| FY2022 | $123.0M | 9.74% |
| FY2021 | $112.1M | 14.86% |
| FY2020 | $97.6M | 15.43% |
| FY2019 | $84.6M | 9.98% |
| FY2018 | $76.9M | 15.49% |
| FY2017 | $66.6M | 7.57% |
| FY2016 | $61.9M | 5.56% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $218.8M | 0.66% |
| Jun 2026 | $217.4M | 0.87% |
| Mar 2026 | $215.5M | 8.27% |
| Dec 2025 | $199.0M | (6.02%) |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| EXEL Exelixis, Inc. compare | $255.8M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. | $218.8M |
| INCY Incyte Corporation compare | $203.2M |
| BBIO BridgeBio Pharma, Inc. compare | $196.0M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.0M |
| ASND Ascendis Pharma A/S compare | $68.3M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement